517 related articles for article (PubMed ID: 10342357)
1. Outcome of treatment of hyperthyroidism.
Bringmann IM; van Leeuwen BL; Hennemann G; Beckett GJ; Toft AD
J Endocrinol Invest; 1999 Apr; 22(4):250-6. PubMed ID: 10342357
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
4. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
5. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
6. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
8. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
9. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
10. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
11. [The clinical and laboratory findings in Graves' multinodular type disease].
Grammaticos P; Vasiliou O; Papanastasiou E; Gerasimou G; Balaris V; Alexandris R; Liaros G; Dedousi E
Hell J Nucl Med; 2006; 9(1):53-9. PubMed ID: 16617399
[TBL] [Abstract][Full Text] [Related]
12. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
14. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
[TBL] [Abstract][Full Text] [Related]
15. Post-ablative hypothyroidism.
Yaqub A; Choudhry MI; Wheaton J; Gress T
W V Med J; 2011; 107(2):37-40. PubMed ID: 21476476
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
17. Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial.
Bal CS; Kumar A; Chandra P
J Clin Endocrinol Metab; 2005 Dec; 90(12):6536-40. PubMed ID: 16189259
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial evaluating a block-replacement regimen during radioiodine therapy.
Bonnema SJ; Grupe P; Boel-Jørgensen H; Brix TH; Hegedüs L
Eur J Clin Invest; 2011 Jul; 41(7):693-702. PubMed ID: 21175612
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
20. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]